From the Editor

Mar 01, 2014
Pharmaceutical Executive
Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.
Feb 01, 2014
Pharmaceutical Executive
Today, there is promise in new approaches that rely on the "other language of biology," using the human body's own circuitry of cells and nerves to induce precisely targeted therapeutic effects against a range of debilitating diseases.
Feb 01, 2014
Pharmaceutical Executive
By Pharmaceutical Executive Editors
For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products
Jan 21, 2014
Pharmaceutical Executive
Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exst. Drugs were still classified as chemicals, developed from the random screening of many thoughts.
Dec 01, 2013
Pharmaceutical Executive
New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry's business model.
Nov 01, 2013
Pharmaceutical Executive
Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.
Oct 01, 2013
Pharmaceutical Executive
Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."
Sep 01, 2013
Pharmaceutical Executive
A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.
Aug 01, 2013
Pharmaceutical Executive
The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China—ironically, the country touted as guarantor of our industry's future.
Jul 02, 2013
Pharmaceutical Executive
By Pharmaceutical Executive Editors
William Looney introduces this year's selection of 15 pharma professionals that, on our view, have real prospects for a future key to the C-suite.
native1_300x100
lorem ipsum